Matinas BioPharma Holdings, Inc.
MTNBHealthcare|Biotechnology|US
$1.19
+0.03 (+2.59%)
DCF Value
$6.44
Cash / Share
$1.78
Clinical Trials (11)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT01731353 FungiScope - A Global Emerging Fungal Infection Registry | Invasive Fungal Disease | Recruiting | 1,000 | — | — | |
| NCT05541107 Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3 | Cryptococcal Meningitis | P3 | Unknown | 270 | RCT, Open-label | MAT2203, Amphotericin B |
| NCT04662528 Safety and Efficacy of MAT9001(Omega-3-pentaenoic Acid) in Subjects With Triglycerides ≥500 mg/dL and <2000 mg/dL | Severe Hypertriglyceridemia | P3 | Withdrawn | — | RCT, Double-blind | Placebo, MAT9001 (omega-3 pentaenoic acid) |
| NCT04177680 Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia | Hypertriglyceridemia | P2 | Completed | 100 | RCT, Open-label | Omega 3 pentaenoic acid, icosapent ethyl |
| NCT03196921 Efficacy and Safety of Oral Encochleated Amphotericin B for the Treatment of Cryptococcal Infection | Cryptococcal Infections | P1P2 | Withdrawn | — | Open-label | Encochleated Amphotericin B |
| NCT02971007 Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC) | Vulvovaginitis, Yeast Infection | P2 | Completed | 137 | RCT, Single-blind | Oral Encochleated Amphotericin B (CAMB), Fluconazole |
| NCT04031833 Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT) | Cryptococcal Meningitis | P1P2 | Completed | 178 | RCT, Open-label | MAT2203, Amphotericin B |
| NCT02629419 CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis | Candidiasis, Chronic Mucocutaneous | P2 | Completed | 4 | Open-label | Amphotericin B |
| NCT02310022 A PK and PD Study of Two Formulations of Omega-3 One Gram Capsules | Hypertriglyceridemia | P1P2 | Completed | 48 | RCT, Open-label | Drug Omega 3, Drug Omega-3 Comparator |
| NCT03167957 Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis | Vulvovaginal Candidiases, Yeast Infection | P2 | Withdrawn | — | RCT, Open-label | Oral Encochleated Amphotericin B (CAMB), Oral Encochleated Amphotericin B (CAMB) |
| NCT03187691 Safety and PK of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal Prophylaxis in Patients Undergoing Induction Chemotherapy for Acute Myelogenous and Lymphoblastic Leukaemia | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | P2 | Withdrawn | — | Open-label | Oral Encochleated Amphotericin B (CAMB) |